Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Rheumatoid arthritis

Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Chen M, Lee I, Chen M, et al

Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease

Annals of the Rheumatic Diseases 2021;80:1393-1399.